Cudetaxestat Polymorphs and Salts for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for autotaxin compounds with suitable properties for therapeutic use, particularly for treating fibrotic diseases and disorders and cancers, as existing treatments may not effectively address these conditions.
Innovation Solution
Development of crystalline forms and salts of a compound of Formula (I), including polymorphic forms and solvates, which exhibit improved solubility, bioavailability, stability, and ease of manufacture, thereby enhancing their efficacy as autotaxin inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If crystalline forms and salts of the autotaxin inhibitor are developed, then solubility and bioavailability are improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies parameter changes by developing multiple crystalline forms (polymorphs) and salt forms of the autotaxin inhibitor, each with different physical properties. By changing the physical state and crystalline structure parameters, the invention optimizes solubility and bioavailability while maintaining manufacturing feasibility through established crystallization and salt formation techniques.
Solution Approach 2:
The patent creates composite material systems by forming salt compounds and solvates of the autotaxin inhibitor. These composite forms combine the inhibitor with counterions or solvent molecules to achieve improved pharmaceutical properties, including enhanced solubility and bioavailability, while remaining manufacturable through standard pharmaceutical processing methods.
2Reliability
If crystalline forms and salts of the autotaxin inhibitor are developed, then bioavailability is improved, but stability requirements become more stringent
Solution Approach 1:
The patent utilizes parameter changes by systematically varying the crystalline structure and physical state of the autotaxin inhibitor to achieve optimal bioavailability. By controlling parameters such as crystal packing, polymorphic form, and salt composition, the invention enhances bioavailability while ensuring stability through selection of appropriate physical forms that resist degradation.
Solution Approach 2:
The patent employs temporary solvate forms and intermediate salt structures that facilitate improved bioavailability during the therapeutic window, while being designed to convert to stable crystalline forms in the body. These temporary forms enhance absorption without compromising overall stability, as they resolve into stable polymorphic forms after administration.
3Reliability
If multiple crystalline forms and salts are provided, then therapeutic efficacy is enhanced, but formulation complexity increases
Solution Approach 1:
The patent applies universality by developing a family of crystalline forms and salt forms that can serve multiple therapeutic functions. These different forms and salts all target the same autotaxin inhibition mechanism, providing enhanced therapeutic efficacy through varied physical properties while maintaining a unified therapeutic approach that can be adapted to different patient needs and formulation requirements.
Solution Approach 2:
The patent enhances therapeutic efficacy by systematically varying physical parameters such as crystalline structure, polymorphic form, and salt composition. These parameter changes allow optimization of different therapeutic attributes (solubility, bioavailability, stability) while maintaining the core autotaxin inhibition function, thereby enhancing overall therapeutic efficacy without proportionally increasing formulation complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms and salts provide significant clinical improvements by effectively inhibiting autotaxin, offering improved therapeutic potential for fibrotic diseases and disorders and cancers.
Implementation Method 1
the crystalline form exhibits an X-ray powder diffraction pattern comprising at least one characteristic peak, wherein said characteristic peak is selected from the group consisting of approximately 7.2, 10.4, 12.0, 14.5, 17.9, 21.5, 21.8, 22.3, 23.5, 25.0, 25.8, 27.2, 27.7, 29.8, 31.6, and 36.7 degrees 2θ
Data Source
AI summary
Disclosed herein are autotaxin inhibitor compounds, polymorphic forms, pharmaceutical compositions, and the method of use and preparation thereof. Some embodiments relate to crystalline forms of Compound 1 and salts thereof.